AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01432769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement high in energy and protein
Description: patients in the standardized diet will receive extra 500 kcal from the dietary supplement
Study NCT03366506 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT03539952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillamine (D1-W12)
Description: Penicillamine during baseline period (D1-W12)
Study NCT00484367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent group therapy
Description: Adolescent group therapy
Study NCT00484367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transitional family therapy
Description: Transitional family therapy
Study NCT03539952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillamine (D1-W12)
Description: Penicillamine during baseline period (D1-W12)
Study NCT03539952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TETA 4HCL (W12-60)
Description: TETA 4HCL during post randomisation and 1st extension period (W12-W60)
Study NCT03539952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillamine (W12-W60)
Description: Penicillamine during rondomisation and 1st extension period period (W12-W60)
Study NCT03539952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TETA 4HCL (60-<W108)
Description: TETA 4HCL during 2nd extension period (W60-\<W108)
Study NCT03539952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TETA 4HCL (60-<W108)
Description: TETA 4HCL during 2nd extension period (W60-\<W108)
Study NCT02469584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small stitch anterior colporrhaphy
Description: A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
Study NCT00324272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin Sealant (Tisseel) used in the Experimental Arm.
Description: For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects).
Study NCT00324272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant (Tisseel) used in the Experimental Arm.
Description: For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects).
Study NCT03505957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeBreak Vascular
Description: SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
Study NCT03908086 — intervention group
Intervention type: OTHER
Intervention: Risk factors in RA cohort
Study NCT03908086 — intervention group
Intervention type: OTHER
Intervention: Risk factors in general population
Study NCT04348136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion, 2.0 mg/kg/week
Study NCT02798445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAPIRS
Description: Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
Study NCT02798445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Multilayer bandages and wound care
Study NCT04684160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-bearing TKA
Study NCT04684160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Study NCT01375439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active search of lower genital tract infections
Description: Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
Study NCT02583360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy
Description: Addition of research HRM along with diagnostic VFSS with parental choice of therapy
Study NCT00329459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan succinate/naproxen sodium
Study NCT00329459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match
Study NCT04430868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle redesign program
Description: In this group, it starts with health education, the participants then change their opinions and experience health activities, and it ends with discussion and sharing their experience.
Study NCT01602744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STOPP/START screening tools for medication intervention
Description: In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
Study NCT00257322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250ug/m\^2 SQ QD with a cap of 500mcg SQ QD
Study NCT04207125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multilevel psychotherapeutic intervention programme
Description: Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes.
Study NCT03642275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCardia4HF
Description: Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
Study NCT00826709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluID Rapid Influenza Test
Description: The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
Study NCT05578560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prehabituation
Description: chemical labyrinthectomy with intratympanically installed gentamicin
Study NCT05578560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D optokinetic stimulation in virtual reality space
Description: 3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.
Study NCT05578560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular training
Description: vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
Study NCT00914966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 inhibitor (human) [C1 INH]
Study NCT01701401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily
Study NCT01701401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT03693066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
Study NCT03693066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine digluconate
Description: In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
Study NCT03693066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT01298076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Anti-VEGF drug for intravitreal injection
Study NCT01298076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Slow-release steroid formulation for intravitreal injection
Study NCT01000805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
Study NCT00681395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: once daily for six days
Study NCT00681395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Once daily for 6 days
Study NCT04264520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Psychoeducation + Skills Intervention
Description: A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
Study NCT03275506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab
Description: Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
Study NCT03275506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy - Bevacizumab
Description: Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
Study NCT04727996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: 120 mg will be administered orally once daily
Study NCT04727996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg will be administered intravenously (IV) once every 3 weeks
Study NCT01769950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choline-PET
Description: Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
Study NCT03835182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound group
Description: Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back
Study NCT03835182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short wave diathermy group
Description: SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes
Study NCT03835182 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: superficial heat, analgesic physical modality and exercise only
Study NCT03719001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
Study NCT03719001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
Study NCT03719001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
Study NCT03719001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tetanic stimulus
Description: A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
Study NCT03719001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased venous pressure
Description: A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
Study NCT03719001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Chloride
Description: CaCl will be administered to increase blood pressure and plasma calcium concentration
Study NCT02916199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cannulation of ampulla of Vater
Description: Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
Study NCT02916199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cannulation of ampulla of Vater
Description: Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
Study NCT00858975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
Study NCT01752998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treating Opioid Patients' Pain and Sadness (TOPPS)
Study NCT01752998 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Study NCT01296620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin Intravenously (IV)
Description: 160 µg/kg daily (QD)
Study NCT01296620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin Invtravenously (IV)
Description: 480 µg/kg daily (QD)
Study NCT02201329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (subcutaneous)
Study NCT02201329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib escalating doses (intravenous)
Study NCT01296620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: Placebo
Study NCT01615185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: full-dose amisulpride
Description: amisulpride 800mg/d
Study NCT01615185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full-dose amisulpride
Description: amisulpride 800mg/d
Study NCT00586001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Cognitive-behavioral treatment in development for emotional disorders
Study NCT04080401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game-based rehabilitation exercise
Description: 4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
Study NCT04080401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional brochures of rehabilitation exercise
Description: 4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
Study NCT03168854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain
Description: Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
Study NCT03059511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Opioid Pain Medicine
Study NCT00430027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4
Study NCT00430027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 30 mg/m\^2, 130mg/m2 IV Q 21 days x 4
Study NCT00430027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial Cetuximab 400 mg/m\^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
Study NCT03168854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.
Study NCT03168854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.
Study NCT04350918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Enery Techniques
Description: Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
Study NCT04350918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Set of patients that had static stretching technique for the treatment for the complaint
Study NCT02516345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
Study NCT02516345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
Study NCT02516345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives
Description: Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
Study NCT00005792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
Study NCT00005792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5
Study NCT00005792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
Study NCT00005792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Rescue
Description: reinfusion of stem cells, Day 0
Study NCT03422744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans bronchial biopsy guided by echo-endoscopic miniprobes
Description: We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
Study NCT03422744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: if first one negative: samples under fluoroscopic control
Description: If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
Study NCT01970735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test